From: Impact of comorbidities in COPD clinical control criteria. The CLAVE study
Univariate analysis | Multivariate analysisa; OR (CI 95%); p-value | ||||
---|---|---|---|---|---|
Total | Controlled COPD | Non-controlled COPD | p-value | ||
Charlson index, n (%) | 4801 (100.0) | 1322 (100.0) | 3479 (100.0) | ||
Mean (SD) | 2.17 (1.54) | 1.90 (1.35) | 2.28 (1.6) | < 0.0001 | |
Comorbidities included in the Charlson index, n (%) | |||||
Myocardial infarction | 484 (10.1) | 128 (9.7) | 356 (10.2) | 0.5714 | 1.03 (0.83–1.28); p = 0.7968 |
Congestive heart failure | 558 (11.6) | 95 (7.2) | 463 (13,3) | < 0.0001 | 1.83 (1.45–2.31); p < 0.0001 |
Peripheral vascular disease | 498 (10.4) | 89 (6.7) | 409 (11.8) | < 0.0001 | 1.80(1.41–2.29); p < 0.0001 |
Cerebrovascular disease | 239 (5.0) | 51 (3.9) | 188 (5.4) | 0.0278 | 1.32 (0.96–1.82); p = 0.0856 |
Dementia | 49 (1.0) | 4 (0.3) | 45 (1.3) | 0.0023 | 3.85 (1.38–10.79); p = 0.0102 |
Pathology of connective tissue | 73 (1.5) | 14 (1.1) | 59 (1.7) | 0.1072 | 1.74 (0.96–3.14); p = 0.0664 |
Ulcer disease | 191 (4.0) | 41 (3.1) | 150 (4.3) | 0.0553 | 1.32 (0.93–1.88); p = 0.1239 |
Mild liver pathology | 220 (4.6) | 49 (3.7) | 171 (4.9) | 0.0736 | 1.42 (1.02–1.97); p = 0.0353 |
Diabetes | 1023 (21.3) | 250 (18.9) | 773 (22.2) | 0.0124 | 1.22 (1.04–1.44); p = 0.0138 |
Diabetes with organic lesion | 173 (3.6) | 24 (1.8) | 149 (4.3) | < 0.0001 | 2.33 (1.50–3.61); p = 0.0002 |
Hemiplegia | 18 (0.4) | 3 (0.2) | 15 (0.4) | 0.4298f | 1.86 (0.53–6.50); p = 0.3299 |
Renal pathology (moderate or severe) | 219 (4.6) | 49 (3.7) | 170 (4.9) | 0.0801 | 1.22 (0.88–1.70); p = 0.2297 |
Solid neoplasm without metastasis | 448 (9.3) | 103 (7.8) | 345 (9.9) | 0.0237 | 1.21 (0.96–1.52); p = 0.1134 |
Leukemia | 18 (0.4) | 3 (0.2) | 15 (0.4) | 0.4298f | 1.77 (0.51–6.19); p = 0.3686 |
Malignant lymphoma | 18 (0.4) | 2 (0.2) | 16 (0.5) | 0.1834f | 3.10 (0.71–13.52); p = 0.1324 |
Liver pathology (moderate or severe) | 73 (1.5) | 13 (1.0) | 60 (1.7) | 0.0608 | 1.89 (1.03–3.48); p = 0.0408 |
Solid metastasis | 18 (0.4) | 3 (0.2) | 15 (0.4) | 0.4298f | 1.97 (0.56–6.87); p = 0.2880 |
AIDS | 30 (0.6) | 7 (0.5) | 23 (0.7) | 0.6052 | 1.46 (0.62–3.44); p = 0.3925 |